- Home
- DRIO vs AIDX Comparison
DRIO vs AIDX Comparison
Compare DRIO & AIDX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | DRIO | AIDX |
|---|---|---|
| Founded | 2011 | N/A |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Medical/Dental Instruments | Precision Instruments |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 61.8M | 58.8M |
| IPO Year | 2013 | N/A |
Fundamental Metrics
Financial Performance| Metric | DRIO | AIDX |
|---|---|---|
| Price | $8.42 | $2.50 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 1 | 0 |
| Target Price | ★ $60.00 | N/A |
| AVG Volume (30 Days) | 7.7K | ★ 311.5K |
| Earning Date | 01-01-0001 | N/A |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 9.05 | N/A |
| Revenue | ★ $7,394,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $16.15 | N/A |
| P/E Ratio | $0.99 | ★ N/A |
| Revenue Growth | ★ 43.02 | N/A |
| 52 Week Low | $0.38 | $2.36 |
| 52 Week High | $17.74 | $14.09 |
Technical Indicators
Market Signals| Indicator | DRIO | AIDX |
|---|---|---|
| Relative Strength Index (RSI) | 34.60 | 5.34 |
| Support Level | $0.56 | N/A |
| Resistance Level | $12.36 | $3.08 |
| Average True Range (ATR) | 0.62 | 0.70 |
| MACD | -0.16 | -0.10 |
| Stochastic Oscillator | 18.74 | 1.89 |
Price Performance
Historical ComparisonAbout DRIO DarioHealth Corp.
DarioHealth Corp is a digital therapeutics (DTx) company delivering personalized evidence-based interventions that are driven by precision data analytics, software, and personalized coaching. Its cross-functional team operates at the intersection of life sciences, behavioral science, and software technology to deliver seamlessly integrated and engaging digital therapeutics interventions. Also platform and suite of solutions deliver personalized and dynamic interventions driven by data analytics and one-on-one coaching for diabetes, hypertension, weight management, musculoskeletal pain, and behavioral health.
About AIDX 20/20 Biolabs Inc. Common Stock
20/20 Biolabs Inc is a commercial stage diagnostics company with the core mission of developing and commercializing clinical laboratory tests for early disease detection and prevention and associated software that is powered by machine learning and real-world data to improve diagnostic accuracy and clinical utility. The company offers two OneTest lab products; OneTest for Cancer that inludes primary MCED blood test and revenue source post-COVID and OneTest for Longevity that consists of inflammatory biomarkers.